Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic Trioxide + Etanercept in Advanced MDS
NCT00093366Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Jun 2004
- Modality
- DNA Intercalators/Alkylators, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of arsenic trioxide and etanercept in myelodysplastic syndrome (MDS), sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Frequency of hematologic response, Efficacy in refractory patients and 2 more. Started Jun 2004; status: completed.
02
Drugs
arsenic trioxideetanercept
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00093366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00093366.